Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …

Monoclonal antibodies have been applied clinically to the diagnosis and therapy of an array
of human disorders, including cancer and infectious diseases, and have been used for the …

In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent
intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII …

Multivalency is one of the hallmarks of antibodies, by which enormous gains in functional
affinity, and thereby improved performance in vivo and in a variety of in vitro assays are …

Division of Ser. No. 989,846, Nov. 20, 1992, abandoned, which is a continuation-in-part of
Ser. No. 796,936, Nov. 25, 1991, abandoned, which is a continuation-in-part of Ser. No …

Over the past two decades, attempts have been made to develop immunotherapy for
patients with cancer. A significant obstacle to the development of successful adoptive …

Bispecific antibodies (bsAbs) are antibodies that can simultaneously bind two distinct targets
or epitopes. Their dual-targeting capacity offers expanded therapeutic potential. Currently …

Targeting angiogenesis is a promising approach to the treatment of solid tumors and age-
related macular degeneration (AMD). Inhibition of vascularization has been validated by the …

US9464139B2 - GITR antigen binding proteins and methods of use thereof - Google Patents
US9464139B2 - GITR antigen binding proteins and methods of use thereof - Google Patents …

Bispecific antibodies are unique macromolecular heterobifunctional cross-linkers with two
different binding specificities within a single molecule. As ideal bioconjugates, they can …